HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laura Mauri Selected Research

zotarolimus

10/2016Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent.
10/2014Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.
8/2014Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
12/2013Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
11/2013Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.
4/2013Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
10/2012Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
4/2011Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.
10/2010Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
2/2010A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Laura Mauri Research Topics

Disease

76Thrombosis (Thrombus)
11/2022 - 06/2004
62Myocardial Infarction
11/2022 - 05/2003
46Hemorrhage
11/2022 - 01/2010
19Stroke (Strokes)
01/2021 - 08/2007
19Coronary Artery Disease (Coronary Atherosclerosis)
01/2018 - 02/2006
13Hypertension (High Blood Pressure)
01/2018 - 04/2014
12Death (Near-Death Experience)
05/2015 - 11/2007
11Cardiovascular Diseases (Cardiovascular Disease)
01/2017 - 10/2007
9Diabetes Mellitus
01/2020 - 11/2008
9ST Elevation Myocardial Infarction
10/2019 - 01/2010
8Ischemic Stroke
04/2021 - 12/2010
7Pathologic Constriction (Stenosis)
12/2009 - 06/2004
6Neurodegenerative Diseases (Neurodegenerative Disease)
02/2022 - 08/2014
6Peripheral Arterial Disease
11/2021 - 05/2013
6Heart Failure
01/2020 - 07/2009
6Atrial Fibrillation
01/2020 - 02/2014
6Ischemia
01/2018 - 12/2012
5Neoplasms (Cancer)
01/2018 - 01/2011
4Neuroblastoma
12/2020 - 01/2019
4Coronary Disease (Coronary Heart Disease)
10/2016 - 01/2004
4Acute Coronary Syndrome
09/2016 - 02/2013
4Infarction (Infarctions)
05/2016 - 08/2008
4Coronary Restenosis
10/2007 - 06/2004
3Brain Diseases (Brain Disorder)
07/2022 - 08/2014
3Parkinson Disease (Parkinson's Disease)
01/2020 - 08/2014
3Myocardial Ischemia (Ischemic Heart Diseases)
09/2016 - 05/2011
3Patent Foramen Ovale
08/2014 - 12/2010
3Transient Ischemic Attack
08/2014 - 12/2010
3AIDS-Related Complex (ARC)
10/2013 - 03/2007
2Peripheral Nervous System Diseases (PNS Diseases)
02/2022 - 01/2017
2Alzheimer Disease (Alzheimer's Disease)
01/2020 - 08/2014
2Renal Insufficiency (Renal Failure)
11/2018 - 11/2010
2Guillain-Barre Syndrome
01/2017 - 03/2012
2Mitral Valve Insufficiency (Mitral Regurgitation)
10/2013 - 07/2009
2Carcinoma (Carcinomatosis)
10/2012 - 07/2010
1Type A Niemann-Pick Disease
07/2022
1Niemann-Pick Diseases (Niemann Pick Disease)
07/2022
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2022
1Globoid Cell Leukodystrophy (Krabbe Disease)
01/2022
1Cystic Fibrosis (Mucoviscidosis)
06/2020
1Multiple Sclerosis
01/2020

Drug/Important Bio-Agent (IBA)

262'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
11/2022 - 12/2010
18Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2020 - 07/2006
18Sirolimus (Rapamycin)FDA Link
10/2017 - 01/2005
18MetalsIBA
10/2015 - 06/2004
17thienopyridineIBA
12/2019 - 12/2010
14zotarolimusIBA
10/2016 - 12/2006
11Paclitaxel (Taxol)FDA LinkGeneric
11/2021 - 03/2007
10Pharmaceutical PreparationsIBA
11/2021 - 06/2004
8salicylhydroxamic acid (SHAM)IBA
01/2020 - 04/2014
7omega-Chloroacetophenone (Mace)IBA
04/2021 - 10/2007
7Clopidogrel (Plavix)FDA Link
01/2020 - 07/2006
6OligosaccharidesIBA
02/2022 - 01/2017
5G(M1) GangliosideIBA
02/2022 - 01/2019
5LipidsIBA
01/2020 - 08/2014
5AnticoagulantsIBA
11/2018 - 02/2014
5StreptokinaseFDA Link
01/2017 - 05/2015
4SphingolipidsIBA
07/2022 - 01/2018
4PolymersIBA
11/2018 - 12/2010
4Tissue Plasminogen Activator (Alteplase)FDA Link
01/2017 - 05/2015
3GangliosidesIBA
02/2022 - 07/2010
3TicagrelorIBA
01/2020 - 09/2016
3CeramidesIBA
01/2019 - 07/2010
3EverolimusFDA Link
11/2018 - 11/2013
3RetinoidsIBA
01/2018 - 09/2008
3Antihypertensive Agents (Antihypertensives)IBA
01/2018 - 11/2015
3Heparin (Liquaemin)FDA LinkGeneric
09/2017 - 10/2011
3bivalirudin (Angiomax)FDA Link
09/2017 - 10/2011
3Prasugrel HydrochlorideFDA Link
09/2016 - 12/2010
2SphingomyelinsIBA
07/2022 - 07/2010
2CDw17 antigen (lactosylceramide)IBA
01/2022 - 07/2010
2Proteins (Proteins, Gene)FDA Link
06/2020 - 08/2014
2DiureticsIBA
01/2020 - 01/2018
2G(M3) GangliosideIBA
01/2020 - 07/2010
2Warfarin (Coumadin)FDA LinkGeneric
01/2020 - 01/2019
2DabigatranFDA Link
01/2020 - 01/2019
2MB Form Creatine KinaseIBA
10/2019 - 05/2003
2TroponinIBA
10/2019 - 05/2013
2Glycoproteins (Glycoprotein)IBA
09/2017 - 02/2008
2AntibodiesIBA
01/2017 - 03/2012
2IsoenzymesIBA
04/2009 - 05/2003
2Creatine Kinase (Creatine Phosphokinase)IBA
04/2009 - 05/2003
1Glycogen Synthase Kinase 3 betaIBA
01/2022
1Psychosine (Galactosylsphingosine)IBA
01/2022
1Detergents (Detergent)IBA
01/2022
1dicarboxydine (DCD)IBA
11/2021
1RivaroxabanIBA
11/2021
1AnionsIBA
06/2020
1G(M1)-oligosaccharideIBA
01/2020

Therapy/Procedure

96Stents
11/2022 - 01/2004
56Therapeutics
11/2022 - 07/2006
40Percutaneous Coronary Intervention
04/2021 - 05/2003
31Drug-Eluting Stents
11/2022 - 06/2004
10Denervation
01/2018 - 04/2014
7Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2020 - 08/2008
4Duration of Therapy
05/2016 - 02/2013
3Catheters
01/2018 - 04/2014
3Secondary Prevention
09/2016 - 12/2012
2Embolic Protection Devices
08/2011 - 04/2010
1Investigational Therapies (Experimental Therapy)
06/2020